Morgan Stanley
DMK

Morgan Stanley’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Morgan Stanley’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,335
Closed -$935 – 8091
2023
Q4 		$935 Sell
1,335
-7
-0.5% -$4 ﹤0.01% 7143
2023
Q3 		$925 Sell
1,342
-18
-1% -$23 ﹤0.01% 7244
2023
Q2 		$3.28K Sell
1,360
-272
-17% -$1.16K ﹤0.01% 7082
2023
Q1 		$13.2K Buy
1,632
+167
+11% +$2.22K ﹤0.01% 6780
2022
Q4 		$17.4K Buy
1,465
+3
+0.2% +$34 ﹤0.01% 6738
2022
Q3 		$20K Sell
1,462
-53
-3% -$1.37K ﹤0.01% 6805
2022
Q2 		$53K Sell
1,515
-60
-4% -$1.87K ﹤0.01% 6585
2022
Q1 		$63K Sell
1,575
-384
-20% -$16.5K ﹤0.01% 6595
2021
Q4 		$83K Buy
1,959
+460
+31% +$28.7K ﹤0.01% 6548
2021
Q3 		$102K Buy
1,499
+34
+2% +$2.49K ﹤0.01% 6367
2021
Q2 		$113K Buy
1,465
+26
+2% +$1.58K ﹤0.01% 6302
2021
Q1 		$95K Buy
1,439
+2
+0.1% +$156 ﹤0.01% 6051
2020
Q4 		$49K Sell
1,437
-43
-3% -$1.91K ﹤0.01% 6169
2020
Q3 		$81K Hold
1,480
– – ﹤0.01% 5524
2020
Q2 		$56K Sell
1,480
-15
-1% -$513 ﹤0.01% 5643
2020
Q1 		$37K Sell
1,495
-58
-4% -$2.46K ﹤0.01% 5577
2019
Q4 		$76K Sell
1,553
-1,414
-48% -$68.5K ﹤0.01% 5742
2019
Q3 		$147K Sell
2,967
-7,849
-73% -$564K ﹤0.01% 5295
2019
Q2 		$984K Buy
10,816
+7,083
+190% +$862K ﹤0.01% 4234
2019
Q1 		$551K Buy
3,733
+1,524
+69% +$295K ﹤0.01% 4489
2018
Q4 		$348K Buy
2,209
+271
+14% +$52K ﹤0.01% 5026
2018
Q3 		$474K Buy
1,938
+276
+17% +$65.4K ﹤0.01% 5035
2018
Q2 		$373K Sell
1,662
-3,672
-69% -$983K ﹤0.01% 5274
2018
Q1 		$1.31M Buy
5,334
+3,330
+166% +$874K ﹤0.01% 4356
2017
Q4 		$617K Buy
2,004
+999
+99% +$329K ﹤0.01% 4850
2017
Q3 		$368K Buy
1,005
+494
+97% +$175K ﹤0.01% 5052
2017
Q2 		$186K Buy
511
+143
+39% +$42.8K ﹤0.01% 5370
2017
Q1 		$110K Buy
368
+29
+9% +$7.32K ﹤0.01% 5563
2016
Q4 		$75K Sell
339
-178
-34% -$35.7K ﹤0.01% 5653
2016
Q3 		$124K Buy
517
+424
+456% +$88.1K ﹤0.01% 5222
2016
Q2 		$19K Sell
93
-2
-2% -$922 ﹤0.01% 5873
2016
Q1 		$40K Buy
95
+17
+22% +$6.07K ﹤0.01% 5696
2015
Q4 		$29K Sell
78
-20
-20% -$6.27K ﹤0.01% 5916
2015
Q3 		$27K Buy
98
+59
+151% +$16.4K ﹤0.01% 5953
2015
Q2 		$12K Buy
39
+25
+179% +$7.55K ﹤0.01% 6269
2015
Q1 		$4K Buy
14
+11
+367% +$4.75K ﹤0.01% 6377
2014
Q4 		$1K Sell
3
-5
-63% -$1.59K ﹤0.01% 6501
2014
Q3 		$3K Buy
8
+5
+167% +$1.47K ﹤0.01% 6407
2014
Q2 		$1K Buy
+3
New +$1.18K ﹤0.01% 6449
2014
Q1 		– Sell
-34
Closed -$15.4K – 6564
2013
Q4 		$15K Buy
+34
New +$14.9K ﹤0.01% 5952

Other funds holding DMK

Clear Point Advisors
Clear Point Advisors Melville, New York $113M AUM 15% 1-Year Est. Return
Old Point Trust & Financial Services N A
Old Point Trust & Financial Services N A Newport News, Virginia $329M AUM 22.88% 1-Year Est. Return

Morgan Stanley's DMK Position: Q1 2024 in Review

Morgan Stanley sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 1,335 shares — an estimated $935 sold.

Morgan Stanley first reported a position in DMK in Q4 2013 and held it in 40 quarters. The position peaked at $1.31M in Q1 2018. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.

  • Morgan Stanley reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
  • Morgan Stanley sold 1,335 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $935.
  • Morgan Stanley first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 40 quarters.
  • Morgan Stanley's DMK Pharmaceuticals Corporation Common Stock position peaked at $1.31M in Q1 2018.
  • 3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.